← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Inhalon Biopharma, Inc.
Morrisville, NC
$12,822,673
Total funding
7
Grants
Funding over time
peak $5.7M · FY2022–25$10M$7.5M$5M$2.5M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$12,822,673 · 7
By mechanism
R44$10,217,217 · 6
SB1$2,605,456 · 1
Investigators at Inhalon Biopharma, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections$1,024,986
R44 · FY2024 · AI
Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV$1,024,945
R44 · FY2025 · AI
IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection$1,024,942
R44 · FY2024 · AI
Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV$1,024,926
R44 · FY2024 · AI
IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection$1,024,879
R44 · FY2025 · AI
SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections$1,023,875
R44 · FY2025 · AI
IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus$1,023,232
R44 · FY2022 · AI
IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus$1,018,961
R44 · FY2023 · AI
Development of IN-003PI as passive immunization against human metapneumovirus infection$1,013,468
R44 · FY2025 · AI
IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A$1,013,003
R44 · FY2025 · AI
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus$999,810
SB1 · FY2023 · AI
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus$996,814
SB1 · FY2024 · AI
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus$608,832
SB1 · FY2025 · AI